CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging Last nail in the coffin for PCI in stable angina? Correction of a pathogenic gene mutation in human embryos The Year in Cardiovascular Medicine 2020: Coronary Intervention A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States

Review ArticleVolume 76, Issue 4, July 2020

JOURNAL:J Am Coll Cardiol. Article Link

Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review

G Marquis-Gravel, DJ Moliterno, SG Goodman et al. Keywords: PCI; trail design; SCAD

ABSTRACT

The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.